MedNews
May 23, 2013 -- Soricimed Biopharma Inc., a private clinical stage
company developing novel cancer therapeutics and diagnostics, is pleased
to announce that it has added a third site and first U.S. site, to its
Phase I clinical trial, with the first patient beginning treatment this
week with anti-cancer agent SOR-C13 at The University of Texas MD
Anderson Cancer Center in Houston, Texas.
Soricimed’s Phase I trial is a multicenter, open-label, dose escalation
study that is taking place at cancer centres in both the United States
and Canada. The trial is designed to assess safety and tolerability in
patients with advanced cancer tumors, with a weighting on ovarian
cancers. The trial will also assess pharmacokinetics, biomarkers and
initial evidence for efficacy.......
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.